'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO

(MedPage Today) -- PARIS -- Nearly every single patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response with just two cycles of neoadjuvant immunotherapy. Patients in the single-arm study...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news